VIP
MRNA icon

Vista Investment Partners’s Moderna MRNA Stock Holding History

Vista Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,464
Closed -$1.64M – 161
2023
Q4 		$1.64M Buy
+16,464
New +$1.38M 0.6% 54

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vista Investment Partners's MRNA Position: Q1 2024 in Review

Vista Investment Partners sold out of Moderna (MRNA) in Q1 2024, closing a stake of 16,464 shares — an estimated $1.64M sold.

Vista Investment Partners first reported a position in MRNA in Q4 2023 and held it in 1 quarter. The position peaked at $1.64M in Q4 2023. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Vista Investment Partners reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Vista Investment Partners sold 16,464 Moderna shares in Q1 2024, an estimated $1.64M.
  • Vista Investment Partners first reported a position in Moderna in Q4 2023 and held it in 1 quarter.
  • Vista Investment Partners's Moderna position peaked at $1.64M in Q4 2023.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Vista Investment Partners's 13F filing for Q1 2024, filed 16 May 2024.